vs
Amentum Holdings, Inc.（AMTM）与汉瑞祥（HSIC）财务数据对比。点击上方公司名可切换其他公司
汉瑞祥的季度营收约是Amentum Holdings, Inc.的1.1倍（$3.4B vs $3.2B），汉瑞祥净利率更高（2.9% vs 1.4%，领先1.6%），汉瑞祥同比增速更快（7.7% vs -5.2%），汉瑞祥自由现金流更多（$338.0M vs $-142.0M），过去两年Amentum Holdings, Inc.的营收复合增速更高（25.6% vs 4.1%）
本公司是总部位于美国达拉斯的跨国技术专业服务企业，面向全球企业、机构及政府部门客户提供工程、技术、建设服务以及科学与专项咨询服务，连续6年蝉联《工程新闻纪录》（ENR）全球顶尖设计企业500强榜首。
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
AMTM vs HSIC — 直观对比
营收规模更大
HSIC
是对方的1.1倍
$3.2B
营收增速更快
HSIC
高出12.9%
-5.2%
净利率更高
HSIC
高出1.6%
1.4%
自由现金流更多
HSIC
多$480.0M
$-142.0M
两年增速更快
AMTM
近两年复合增速
4.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.2B | $3.4B |
| 净利润 | $44.0M | $101.0M |
| 毛利率 | 10.1% | 30.9% |
| 营业利润率 | 4.3% | 4.7% |
| 净利率 | 1.4% | 2.9% |
| 营收同比 | -5.2% | 7.7% |
| 净利润同比 | 266.7% | 7.4% |
| 每股收益（稀释后） | $0.18 | $0.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMTMHSIC
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.9B | $3.4B | ||
| Q3 25 | — | $3.3B | ||
| Q2 25 | $3.6B | $3.2B | ||
| Q1 25 | $3.5B | $3.2B | ||
| Q4 24 | $3.4B | $3.2B | ||
| Q3 24 | $2.2B | $3.2B | ||
| Q2 24 | $2.1B | $3.1B |
净利润AMTMHSIC
| Q1 26 | $44.0M | — | ||
| Q4 25 | $40.0M | $101.0M | ||
| Q3 25 | — | $101.0M | ||
| Q2 25 | $10.0M | $86.0M | ||
| Q1 25 | $4.0M | $110.0M | ||
| Q4 24 | $12.0M | $94.0M | ||
| Q3 24 | $26.0M | $99.0M | ||
| Q2 24 | $-26.0M | $104.0M |
毛利率AMTMHSIC
| Q1 26 | 10.1% | — | ||
| Q4 25 | 10.6% | 30.9% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | 10.3% | 31.4% | ||
| Q1 25 | 10.5% | 31.6% | ||
| Q4 24 | 10.6% | 31.1% | ||
| Q3 24 | 9.0% | 31.3% | ||
| Q2 24 | 9.6% | 32.5% |
营业利润率AMTMHSIC
| Q1 26 | 4.3% | — | ||
| Q4 25 | 3.4% | 4.7% | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | 2.9% | 4.7% | ||
| Q1 25 | 3.2% | 5.5% | ||
| Q4 24 | 3.9% | 4.9% | ||
| Q3 24 | 1.2% | 4.9% | ||
| Q2 24 | 4.2% | 5.1% |
净利率AMTMHSIC
| Q1 26 | 1.4% | — | ||
| Q4 25 | 1.0% | 2.9% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 0.3% | 2.7% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 0.4% | 2.9% | ||
| Q3 24 | 1.2% | 3.1% | ||
| Q2 24 | -1.2% | 3.3% |
每股收益（稀释后）AMTMHSIC
| Q1 26 | $0.18 | — | ||
| Q4 25 | $0.16 | $0.85 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | $0.04 | $0.70 | ||
| Q1 25 | $0.02 | $0.88 | ||
| Q4 24 | $0.05 | $0.75 | ||
| Q3 24 | $0.31 | $0.78 | ||
| Q2 24 | $-0.29 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $156.0M |
| 总债务越低越好 | $3.9B | $2.3B |
| 股东权益账面价值 | $4.6B | $3.2B |
| 总资产 | $11.2B | $11.2B |
| 负债/权益比越低杠杆越低 | 0.86× | 0.71× |
8季度趋势，按日历期对齐
现金及短期投资AMTMHSIC
| Q1 26 | $247.0M | — | ||
| Q4 25 | $437.0M | $156.0M | ||
| Q3 25 | — | $136.0M | ||
| Q2 25 | $738.0M | $145.0M | ||
| Q1 25 | $546.0M | $127.0M | ||
| Q4 24 | $522.0M | $122.0M | ||
| Q3 24 | $452.0M | $126.0M | ||
| Q2 24 | — | $138.0M |
总债务AMTMHSIC
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $4.5B | $2.1B | ||
| Q1 25 | $4.7B | $2.0B | ||
| Q4 24 | $4.7B | $1.8B | ||
| Q3 24 | $4.7B | $1.9B | ||
| Q2 24 | — | $1.9B |
股东权益AMTMHSIC
| Q1 26 | $4.6B | — | ||
| Q4 25 | $4.5B | $3.2B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | $4.5B | $3.4B | ||
| Q1 25 | $4.4B | $3.3B | ||
| Q4 24 | $4.5B | $3.4B | ||
| Q3 24 | $4.5B | $3.5B | ||
| Q2 24 | $303.0M | $3.5B |
总资产AMTMHSIC
| Q1 26 | $11.2B | — | ||
| Q4 25 | $11.5B | $11.2B | ||
| Q3 25 | — | $11.1B | ||
| Q2 25 | $11.8B | $10.9B | ||
| Q1 25 | $12.0B | $10.5B | ||
| Q4 24 | $11.9B | $10.2B | ||
| Q3 24 | $12.0B | $10.6B | ||
| Q2 24 | — | $10.3B |
负债/权益比AMTMHSIC
| Q1 26 | 0.86× | — | ||
| Q4 25 | 0.88× | 0.71× | ||
| Q3 25 | — | 0.64× | ||
| Q2 25 | 1.01× | 0.61× | ||
| Q1 25 | 1.06× | 0.59× | ||
| Q4 24 | 1.05× | 0.54× | ||
| Q3 24 | 1.05× | 0.54× | ||
| Q2 24 | — | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-136.0M | $381.0M |
| 自由现金流经营现金流 - 资本支出 | $-142.0M | $338.0M |
| 自由现金流率自由现金流/营收 | -4.4% | 9.8% |
| 资本支出强度资本支出/营收 | 0.2% | 1.3% |
| 现金转化率经营现金流/净利润 | -3.09× | 3.77× |
| 过去12个月自由现金流最近4个季度 | $272.0M | $573.0M |
8季度趋势，按日历期对齐
经营现金流AMTMHSIC
| Q1 26 | $-136.0M | — | ||
| Q4 25 | $270.0M | $381.0M | ||
| Q3 25 | — | $174.0M | ||
| Q2 25 | $106.0M | $120.0M | ||
| Q1 25 | $57.0M | $37.0M | ||
| Q4 24 | $110.0M | $204.0M | ||
| Q3 24 | — | $151.0M | ||
| Q2 24 | — | $296.0M |
自由现金流AMTMHSIC
| Q1 26 | $-142.0M | — | ||
| Q4 25 | $261.0M | $338.0M | ||
| Q3 25 | — | $141.0M | ||
| Q2 25 | $100.0M | $88.0M | ||
| Q1 25 | $53.0M | $6.0M | ||
| Q4 24 | $102.0M | $168.0M | ||
| Q3 24 | — | $117.0M | ||
| Q2 24 | — | $259.0M |
自由现金流率AMTMHSIC
| Q1 26 | -4.4% | — | ||
| Q4 25 | 6.6% | 9.8% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | 2.8% | 2.7% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 3.0% | 5.3% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 8.3% |
资本支出强度AMTMHSIC
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 1.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 1.2% |
现金转化率AMTMHSIC
| Q1 26 | -3.09× | — | ||
| Q4 25 | 6.75× | 3.77× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | 10.60× | 1.40× | ||
| Q1 25 | 14.25× | 0.34× | ||
| Q4 24 | 9.17× | 2.17× | ||
| Q3 24 | — | 1.53× | ||
| Q2 24 | — | 2.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMTM
| Global Engineering Solutions Segment | $1.9B | 59% |
| Other U.S.Government Agencies | $400.0M | 12% |
| Fixed Price Contract | $380.0M | 12% |
| Commercial And International | $226.0M | 7% |
| Time And Materials Contract | $171.0M | 5% |
| Sales Channel Through Intermediary | $78.0M | 2% |
| Equity Method Investee | $50.0M | 2% |
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
